ProMark® Risk Score

This policy provides limited coverage of the ProMark® test for patients with early-stage, needle biopsy–proven prostate cancer to assist in identifying candidates for conservative (active surveillance) management rather than definitive surgery or radiation. No other indications, documentation, limitations, or frequency limits are specified in the policy text.

"ProMark is covered for patients with early-stage, needle biopsy–proven prostate cancer to help determine suitability for conservative (active surveillance) management instead of definitive surgery ..."

Sign up to see full coverage criteria, indications, and limitations.